A plain-language guide

X-linked adrenoleukodystrophy

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Growing map · 34 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. X-linked adrenoleukodystrophy is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's X-linked adrenoleukodystrophy?

X-linked adrenoleukodystrophy is an inherited peroxisomal disorder that results from variants in the ABCD1 gene. ABCD1 normally helps break down very long-chain fatty acids (VLCFAs); when it fails, VLCFAs build up in the nervous system and the adrenal glands. It is the most common peroxisomal disorder and is X-linked, so it mainly affects males, though female carriers can develop milder symptoms. Presentations span a childhood cerebral form, an adult adrenomyeloneuropathy, and adrenal insufficiency. This entry confirms ABCD1 as the gene.

Also indexed asORPHA:43, MONDO:0018544
Features mapped14
Treatments mapped5
Published sources14
Last reviewed2026-08-04

Signs and symptoms

Elevated circulating long chain fatty acid concentration

In X-linked adrenoleukodystrophy, a faulty ABCD1 gene impairs the way cells break down certain fats, so saturated very long chain fatty acids (VLCFA) build up in the blood, the nervous system, and the adrenal glands. This buildup is the core biochemical signature of the condition.

Limited evidenceSource: PMID:41853938
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:18759549, PMID:21399389, OMIM:300100
Notesplain_language confirmed from PMID:18759549 via curation 2026-06-14. plain_language confirmed from PMID:21399389 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:300100 -> PMID:41853938 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Abnormal cerebral white matter morphology

In the cerebral form of X-ALD, the brain's white matter (the insulated wiring that connects brain regions) breaks down. MRI shows spreading areas of demyelination, which track with the loss of thinking, vision, and movement skills.

Limited evidenceSource: PMID:38034003
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:19627707, OMIM:300100
Notesplain_language confirmed from PMID:19627707 via curation 2026-06-18 [carrie (curation)]. | regrounded primary OMIM:300100 -> PMID:38034003 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Impaired vibration sensation at ankles

In the adult spinal-cord form of X-ALD (adrenomyeloneuropathy), the nerves carrying position and vibration signals degenerate. People lose the ability to feel vibration in the feet and become unsteady, especially in the dark, a pattern called sensory ataxia.

Limited evidenceSource: PMID:32934269
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesOMIM:300100
Notesplain_language confirmed from PMID:32934269 via curation 2026-06-18 [carrie (curation)]. | regrounded primary OMIM:300100 -> PMID:32934269 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Seizure

In the childhood cerebral form, seizures can occur as the brain white matter is progressively affected.

Limited evidenceSource: PMID:41986485
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesOMIM:300100
Notesplain_language confirmed from PMID:41986485 via curation 2026-06-14. | regrounded primary OMIM:300100 -> PMID:41986485 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Polyneuropathy

Adrenomyeloneuropathy, the adult form of X-ALD, slowly damages both the spinal cord and the peripheral nerves. This combination produces stiff, weak legs together with nerve-related sensory loss that worsens over years.

Limited evidenceSource: PMID:34560537
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:39020416, OMIM:300100
Notesplain_language confirmed from PMID:39020416 via curation 2026-06-18 [carrie (curation)]. | regrounded primary OMIM:300100 -> PMID:34560537 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Urinary bladder sphincter dysfunction

Spinal-cord involvement in X-ALD often disrupts bladder control. People may develop urgency, frequency, or difficulty emptying the bladder as the disease progresses, alongside the leg stiffness of adrenomyeloneuropathy.

Limited evidenceSource: PMID:39020416
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:32934269, ORPHA:43
Notesplain_language confirmed from PMID:32934269 via curation 2026-06-18 [carrie (curation)]. | regrounded primary ORPHA:43 -> PMID:39020416 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Hearing impairment

In the cerebral form of X-linked adrenoleukodystrophy, hearing can be affected. In one pediatric cohort, visual or hearing impairment was among the neurologic symptoms, reported in about a third of children with cerebral disease.

Limited evidenceSource: PMID:41986485
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesOMIM:300100
Notesplain_language confirmed from PMID:41986485 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:300100 -> PMID:41986485 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

X-linked recessive inheritance

The condition is X-linked: the ABCD1 gene sits on the X chromosome, so males are typically affected, while female carriers may have milder, later-onset symptoms.

Limited evidenceSource: PMID:41667276
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:18759549, OMIM:300100
Notesplain_language confirmed from PMID:18759549 via curation 2026-06-14. | regrounded primary OMIM:300100 -> PMID:41667276 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Primary adrenal insufficiency

Adrenal insufficiency — adrenal glands that cannot make enough of their hormones — is common in X-linked adrenoleukodystrophy. Across studies most males with X-ALD develop adrenal failure, while it is uncommon in women who carry the condition.

Limited evidenceSource: PMID:38034003
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:19627707, PMID:32934269, OMIM:300100
Notesplain_language confirmed from PMID:19627707 via curation 2026-06-14. plain_language confirmed from PMID:32934269 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:300100 -> PMID:38034003 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Hyperpigmentation of the skin

When X-ALD damages the adrenal glands, the body makes extra ACTH, which darkens the skin and the linings of the mouth. This bronzing or darkening can be an early outward sign of the adrenal failure that often comes with X-ALD.

Limited evidenceCurated reference: OMIM:300100
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:19627707
Notesplain_language confirmed from PMID:19627707 via curation 2026-06-18 [carrie (curation)].
Last reviewed2026-06-18

Visual impairment

Vision can be affected in the cerebral form of X-linked adrenoleukodystrophy. In one pediatric cohort, visual or hearing impairment was reported in about a third of children with cerebral disease.

Limited evidenceSource: PMID:41986485
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43
Notesplain_language confirmed from PMID:41986485 via curation 2026-06-25 [claude-draft]. | regrounded primary ORPHA:43 -> PMID:41986485 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Cognitive impairment

The childhood cerebral form brings progressive cognitive decline, along with vision and hearing loss, as demyelination spreads through the brain.

Limited evidenceSource: PMID:8009141
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41986485, ORPHA:43
Notesplain_language confirmed from PMID:41986485 via curation 2026-06-14. | regrounded primary ORPHA:43 -> PMID:8009141 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Progressive spastic paraparesis

Adult X-linked adrenoleukodystrophy often shows up as adrenomyeloneuropathy, a slowly worsening problem of the spinal cord and nerves. A central feature is progressive spastic paraparesis: stiffness and weakness in the legs that gets worse over time.

Limited evidenceSource: PMID:39020416
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:18759549, ORPHA:43
Notesplain_language confirmed from PMID:18759549 via curation 2026-06-14. plain_language confirmed from PMID:39020416 via curation 2026-06-25 [claude-draft]. | regrounded primary ORPHA:43 -> PMID:39020416 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Increased circulating ACTH level

In X-linked adrenoleukodystrophy with adrenal involvement, the pituitary signal ACTH is often raised because the adrenal glands respond poorly. In a small group of adrenomyeloneuropathy patients, all had elevated ACTH at the start.

Limited evidenceSource: PMID:21399389
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43
Notesplain_language confirmed from PMID:21399389 via curation 2026-06-25 [claude-draft]. | regrounded primary ORPHA:43 -> PMID:21399389 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

How it is diagnosed

X-linked adrenoleukodystrophy

Diagnosed using: ABCD1 gene testing.

Limited evidenceSource: PMID:41986485
The source text this rests on
“Clinical features, adrenal function, brain MRI findings, and ABCD1 mutations were analyzed.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41986485 via curation 2026-06-25
Last reviewed2026-06-25

X-linked adrenoleukodystrophy

Diagnosed using: brain MRI with Loes score.

Limited evidenceSource: PMID:41986485
The source text this rests on
“Loes scores were determined for cerebral ALD (cALD).”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41986485 via curation 2026-06-25
Last reviewed2026-06-25

X-linked adrenoleukodystrophy

Diagnosed using: newborn screening (C26:0-lysophosphatidylcholine).

Limited evidenceSource: PMID:42068145
The source text this rests on
“C26:0-Lysophosphatidylcholine (C26:0-Lyso-PC) has emerged as a robust biomarker for X-ALD and a candidate for newborn screening programs.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:42068145 via curation 2026-06-25
Last reviewed2026-06-25

X-linked adrenoleukodystrophy

Diagnosed using: plasma very long chain fatty acids (VLCFA).

Limited evidenceSource: PMID:32934269
The source text this rests on
“The serum concentration of C26:0 was superior to C24:0 for the detection of X-ALD.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:32934269 via curation 2026-06-25
Last reviewed2026-06-25

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation can halt the cerebral form when carried out early (presymptomatic or early-symptomatic), which is why newborn screening matters; it does not reverse damage that has already occurred.

Used to help with: X-linked adrenoleukodystrophy.

Limited evidenceSource: PMID:18759549
The source text this rests on
“Hematopoietic stem cell transplantation has been reported to be effective in presymptomatic or early symptomatic…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:18759549 via curation 2026-06-14
Last reviewed2026-06-14

adrenal hormone replacement

Adrenal hormone (steroid) replacement is needed by everyone who develops adrenal insufficiency; it treats the adrenal failure but does not stop the neurological disease.

Used to help with: X-linked adrenoleukodystrophy.

Limited evidenceSource: PMID:18759549
The source text this rests on
“Hormone-replacement therapy is necessary in all patients with adrenal insufficiency.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:18759549 via curation 2026-06-14
Last reviewed2026-06-14

allogeneic hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation is used for the early cerebral form of X-linked adrenoleukodystrophy. It has been reported to work when given before symptoms appear or very early, and in a pediatric cohort early-stage cerebral patients who received a transplant trended toward better survival.

Used to help with: X-linked adrenoleukodystrophy.

Limited evidenceSource: PMID:18759549
The source text this rests on
“Hematopoietic stem cell transplantation has been reported to be effective in presymptomatic or early symptomatic CCALD, and may well also be a final therapeutic option in early ACALD patients.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:18759549 via curation 2026-06-25
Last reviewed2026-06-25

elivaldogene autotemcel (Skysona)

Elivaldogene autotemcel, sold as Skysona, is a gene therapy for the cerebral form of X-linked adrenoleukodystrophy. It was first approved in the EU in 2021 for early cerebral disease in patients under 18 with an ABCD1 mutation when a matched sibling stem-cell donor is not available.

Used to help with: X-linked adrenoleukodystrophy.

Limited evidenceSource: PMID:34424497
The source text this rests on
“Elivaldogene autotemcel (SKYSONA™, eli-cel; Lenti-D™ gene therapy) is a gene therapy that has been developed by bluebird bio for the treatment of cerebral adrenoleukodystrophy (CALD), a rare, X-linked genetic disease that mainly affects the nervous system and adrenal glands.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:34424497 via curation 2026-06-25
Last reviewed2026-06-25

Lorenzo's oil

Lorenzo's oil is a dietary fat mixture studied in X-linked adrenoleukodystrophy. It did not prove effective for the inflammatory cerebral form, though the review noted that people without symptoms, possibly some adrenomyeloneuropathy cases without brain involvement, and female carriers might benefit from it together with a diet low in very long chain fats. Its benefit remains limited and uncertain.

Used to help with: X-linked adrenoleukodystrophy.

Limited evidenceSource: PMID:18759549
The source text this rests on
“Lorenzo's oil did not prove to be effective in cerebral inflammatory disease variants, but asymptomatic patients, and speculatively AMN variants without cerebral involvement, as well as female carriers may benefit from early intake of oleic and erucic acids in addition to VLCFA restriction.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:18759549 via curation 2026-06-25
Last reviewed2026-06-25

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 14 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

OMIM:300100 · Orphanet/HPO annotations for Adrenoleukodystrophy
ORPHA:43 · Orphanet/HPO annotations for X-linked adrenoleukodystrophy
PMID:18759549 · Therapy of X-linked adrenoleukodystrophy.
PMID:21399389 · Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible?
PMID:32934269 · Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-Adrenoleukodystrophy.
PMID:34424497 · Elivaldogene Autotemcel: First Approval.
PMID:34560537 · Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies.
PMID:38034003 · X-linked adrenoleukodystrophy and primary adrenal insufficiency.
PMID:39020416 · Burden of illness and mortality in men with Adrenomyeloneuropathy: a retrospective cohort study.
PMID:41667276 · Adrenoleukodystrophy in adults: phenotypic characterisation and natural history in a large cohort.
PMID:41853938 · Natural History of Clinical Phenotypes and Their Biochemical Correlates in Adult X-Linked Adrenoleukodystrophy.
PMID:41986485 · Pediatric X-linked adrenoleukodystrophy: phenotypes, variants, and HSCT outcomes.
PMID:42068145 · Evaluation of c26:0-Lyso-Phosphatidylcholine Levels in X-Linked Adrenoleukodystrophy: Diagnosis and Biochemical Monitori
PMID:8009141 · [Symptomatic heterozygotic adrenoleukodystrophy in adults. 10 cases].

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.